Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL DG PHARM : revenue, balance sheet and financial ratios

SPFPL DG PHARM is a French company founded 4 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in MANE (31260), this company of category PME shows in 2025 a net income positive of 112 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - SPFPL DG PHARM (SIREN 908768948)
Kennzahl 2025 2023
Umsatz N/C N/C
Nettoergebnis 111 908 € 102 655 €
EBITDA -1 074 € -10 201 €
Nettomarge N/C N/C

Umsatz und Gewinn- und Verlustrechnung

In 2025, SPFPL DG PHARM generates positive net income of 112 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2023-2025: 103 k€ -> 112 k€.

EBITDA (2025) ?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit

-1 074 €

EBIT (2025) ?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen

-721 €

Nettoergebnis (2025) ?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Formel
Ordentliches Ergebnis + Außerordentliches Ergebnis - Ertragsteuern

111 908 €

Chargement du compte de résultat...

Évolution graphique

Anzeigen :

Aktiva

Chargement des données...

Passiva

Chargement des données...

Solvenz- und Verschuldungskennzahlen

The debt ratio (= Financial debt / Equity x 100) stands at 52%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.8 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.

Verschuldungsgrad (2025) ?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible
50-100% : Moderat
> 100% : Hoch

52.438%

Finanzielle Autonomie (2025) ?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Formel
(Eigenkapital / Bilanzsumme) x 100
Interpretation
> 30% : Gute Autonomie
20-30% : Durchschnitt
< 20% : Faible

34.388%

Rückzahlungsfähigkeit (2025) ?
Rückzahlungsfähigkeit
Definition
Anzahl der Jahre zur Schuldenrückzahlung mit dem Cashflow.
Formel
Dettes financières / CAF
Interpretation
< 3 Jahre : Ausgezeichnet
3-5 Jahre : Angemessen
> 5 Jahre : Attention

3.812

Entwicklung der Solvenzkennzahlen
SPFPL DG PHARM

Positionnement sectoriel

Debt ratio
52.44 2025
2023
2025
Q1: 0.14
Méd: 27.24
Q3: 146.28
Average -13 pts über 2 Jahre

In 2025, the debt ratio of SPFPL DG PHARM (52.44) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
34.39% 2025
2023
2025
Q1: 17.38%
Méd: 54.75%
Q3: 87.41%
Average -6 pts über 2 Jahre

In 2025, the financial autonomy of SPFPL DG PHARM (34.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
3.81 years 2025
2023
2025
Q1: 0.0 years
Méd: 0.77 years
Q3: 6.12 years
Average -11 pts über 2 Jahre

In 2025, the repayment capacity of SPFPL DG PHARM (3.81) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquiditätskennzahlen

The liquidity ratio (= Current assets / Current liabilities) stands at 31450.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquiditätsquote (2025) ?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut
1-1.5 : Angemessen
< 1 : Risque de liquidité

31450.0

Zinsdeckung (2025) ?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Formel
EBIT / Zinsaufwendungen
Interpretation
> 3 : Komfortabel
1.5-3 : Acceptable
< 1.5 : Risiko

-198.138

Entwicklung der Liquiditätskennzahlen
SPFPL DG PHARM

Positionnement sectoriel

Liquidity ratio
31450.0 2025
2023
2025
Q1: 159.67
Méd: 1116.63
Q3: 6512.12
Excellent +47 pts über 2 Jahre

In 2025, the liquidity ratio of SPFPL DG PHARM (31450.00) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-198.14x 2025
2023
2025
Q1: -191.54x
Méd: -25.42x
Q3: 0.0x
Average -20 pts über 2 Jahre

In 2025, the interest coverage of SPFPL DG PHARM (-198.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positionnement de SPFPL DG PHARM dans son secteur

Vergleich mit der Branche Fonds de placement et entités financières similaires

Bewertungsschätzung

Based on 170 transactions of similar company sales (all years), the value of SPFPL DG PHARM is estimated at 1 160 128 € (range 719 110€ - 1 804 364€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
719k€ 1160k€ 1804k€
1 160 128 € Range: 719 110€ - 1 804 364€
NAF 5 all-time

Valuation method used

Net Income Multiple
111 908 € × 10.4x = 1 160 128 €
Range: 719 111€ - 1 804 364€

Only this financial indicator is available for this company.

Bewertungsentwicklung

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL DG PHARM with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL DG PHARM

What is the revenue of SPFPL DG PHARM ?

The revenue of SPFPL DG PHARM is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL DG PHARM profitable?

Yes, SPFPL DG PHARM generated a net profit of 112 k€ in 2025.

Where is the headquarters of SPFPL DG PHARM ?

The headquarters of SPFPL DG PHARM is located in MANE (31260), in the department Haute-Garonne.

Where to find the tax return of SPFPL DG PHARM ?

The tax return of SPFPL DG PHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL DG PHARM operate?

SPFPL DG PHARM operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.